Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: The Athero Gene study

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 1, 2009, Pages 49-57

  Tregouet, D A ^a,b   Schnabel, R ^c   Alessi, M C ^a   Godefroy, T ^a,b   Declerck, P J ^d   Nicaud, V ^a,b   Munzel, T ^c   Bickel, C ^e   Rupprecht, H J ^c   Lubos, E ^c   Zeller, T ^c   Juhan Vague, I ^a   Blankenberg, S ^c   Tiret, L ^a,b   Morange, Pierre Emmanuel ^a,f  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e Bundeswehrzentralkrankenhaus ^*  (Germany)

^f TIMONE HOSPITAL   (France)

Author keywords

Cardiovascular diseases; Coronary disease; Fibrinolysis; TAFI

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FEMALE; FIBRINOLYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR;

AGED; CARBOXYPEPTIDASE B; CARBOXYPEPTIDASE U; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS;

EID: 57749176449     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03221.x     Document Type: Article

References (30)

1. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
2. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
3. Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
4. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
5. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/ thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-35.
6. Kokame K, Zheng X, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 1998; 273: 12135-9.
7. Boffa MB, Koschinsky ML. Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40: 431-42.
8. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
9. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
10. Willemse JL, Hendriks DF. Measurement of procarboxypeptidase U (TAFI) in human plasma: A laboratory challenge. Clin Chem 2006; 52: 30-6.
11. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-23.
12. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004; 279: 27896-904.
13. Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26: 423-8.
14. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE; HIFMECH Study Group. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.
15. Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: The PRIME Study. J Thromb Haemost 2005; 3: 1503-10.
16. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
17. Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122: 958-65.
18. Santamaría A, Martínez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 2004; 89: 880-1.
19. Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, PRIME Study group. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI). Thromb Haemost 2003; 89: 554-60.
20. Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 2003; 90: 92-100.
21. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
22. Blankenberg S, Godefroy T, Poirier O, Rupprecht HJ, Barbaux S, Bickel C, Nicaud V, Schnabel R, Kee F, Morrison C, Evans A, Lackner KJ, Cambien F, Münzel T, Tiret L, AtheroGene Investigators. Haplotypes of the caspase-1 gene, plasma caspase-1 levels and cardiovascular risk. Circ Res 2006; 99: 102-8.
23. Frère C, Tregouet DA, Morange PE, Saut N, Kouassi D, Juhan-Vague I, Tiret L, Alessi MC. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood 2006; 108: 1562-8.
24. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038-9.
25. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
26. Guimaraes AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: Comparison of different assays. Br J Haematol 2004; 124: 659-65.
27. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
28. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.
29. Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007; 27: 955-62.
30. Boffa MB, Maret D, Hamill JD, Bastajian N, Crainich P, Jenny NS, Tang Z, Macy EM, Tracy RP, Franco RF, Nesheim ME, Koschinsky ML. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: A functional analysis. Blood 2008; 111: 183-9.